

Association between estimated cardiorespiratory fitness and breast cancer: a prospective cohort study

Rebecca A G Christensen ¹, Julia A Knight,^{1,2} Rinku Sutradhar,^{1,3,4} Jennifer D Brooks¹

► Additional supplemental material is published online only. To view, please visit the journal online (<http://dx.doi.org/10.1136/bjsports-2021-104870>).

¹Public Health Sciences, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada

²Lunenfeld-Tanenbaum Research Institute, Sinai Health, Toronto, Ontario, Canada

³Cancer Research Program, ICES, Toronto, Ontario, Canada

⁴Institute of Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada

Correspondence to

Dr Rebecca A G Christensen, Dalla Lana School of Public Health, University of Toronto, Toronto, Canada; r.christensen@mail.utoronto.ca

Accepted 4 June 2023
Published Online First
19 June 2023

ABSTRACT

Objective To examine the association between cardiorespiratory fitness (CRF) and the risk of breast cancer in postmenopausal women.

Methods This study used data from 17 840 cancer-free postmenopausal women with a CRF assessment from the UK Biobank. High estimated CRF (eCRF) was categorised as being ≥ 80 th percentile within 10-year age bands. Fine and Gray regression was used to examine the association between eCRF and breast cancer risk, accounting for both non-breast cancer diagnoses and all-cause mortality as competing risks. Age was used as the time scale. Several different models were produced, including those adjusting for known breast cancer risk factors, and stratified by measures of body fat (body mass index and per cent body fat).

Results Over a median follow-up of 11.0 years there were 529 cases of invasive breast cancer, 1623 cases of non-breast cancer disease and 241 deaths. With adjustment for breast cancer risk factors, high eCRF was associated with a 24% (subdistribution HR (SDHR) 0.76, 95% CI 0.60 to 0.97) lower risk of breast cancer. When stratified by measures of body fat, we found evidence of effect measure modification. Mainly, having high eCRF was only associated with a lower risk of breast cancer among those classified as having overweight/obesity (SDHR 0.33, 95% CI 0.11 to 1.01) or percentage body fat above the 1st quintile (SDHR 0.65, 95% CI 0.45 to 0.94).

Conclusion Having higher CRF may be a protective factor against breast cancer in postmenopausal women but only for women with elevated body fat.

INTRODUCTION

Established postmenopausal breast cancer risk factors include having a family history of the disease,^{1 2} the use of hormone replacement therapy,²⁻⁴ early age at menarche^{2 5} and increased body mass index (BMI).⁶⁻⁸ One example of a potentially modifiable risk factor is physical activity. Prior research has found that participating in moderate to vigorous physical activity is associated with a lower risk of breast cancer, especially in postmenopausal women.⁸

Cardiorespiratory fitness (CRF) is the ability of a body's respiratory and circulatory system to provide oxygen to skeletal muscles during sustained physical activity. The better these systems are at delivering oxygen, the longer an activity can be maintained at a given endurance. This is an indication of physical fitness. CRF is, therefore, an assessment of the cumulative interrelationship between physical activity,⁹ and other lifestyle (eg,

WHAT IS ALREADY KNOWN ON THIS TOPIC

⇒ Higher body mass index (BMI) or per cent body fat and lower physical activity are risk factors for breast cancer in postmenopausal women.

WHAT THIS STUDY ADDS

⇒ Findings from this study suggest that having high cardiorespiratory fitness (CRF) may be associated with a lower risk of breast cancer in postmenopausal women.
⇒ The relationship between CRF and breast cancer appears to be modified by BMI and per cent body fat whereby CRF may only be associated with a lower risk of breast cancer in those with overweight/obesity or with a percentage body fat above the first quintile.
⇒ CRF was significantly associated with breast cancer, independent of physical activity.

HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY

⇒ CRF may be a new target for clinicians to decrease postmenopausal women's risk of breast cancer, in particular for women with elevated body fat percentage.
⇒ Consistent participation in physical activity to improve CRF may be required to lower a woman's risk of breast cancer.

smoking),¹⁰ physiological (eg, adiposity)^{11 12} and genetic factors.¹³

The aerobic hypothesis put forth by Koch *et al* postulates that a key mechanism of disease and health relates to how well the body can metabolise oxygen (which is partly assessed by CRF).¹⁴ Studies of rodents bred for high aerobic capacity (an assessment of CRF) have found that higher aerobic capacity is associated with greater longevity,¹⁴ as well as a lower incidence of risk factors (eg, insulin resistance) associated with chronic diseases including breast cancer.¹⁵ There is also substantial evidence in humans to support that higher CRF is associated with a lower risk of disease and death.¹⁶ However, while having higher inherent CRF is associated with lower breast cancer incidence and severity in rats,¹⁷ no study to date has examined the relationship between CRF and breast cancer risk in humans.¹⁷ The objective of this study was to examine the association between CRF and incident invasive breast cancer in postmenopausal women. Understanding the relationship between CRF and risk may inform interventions for breast cancer prevention.



© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.

To cite: Christensen RAG, Knight JA, Sutradhar R, *et al.* *Br J Sports Med* 2023;**57**:1238–1247.

METHODS

Study population

The UK Biobank study is a large population-based cohort that recruited approximately 500 000 adults aged 37–73 years from 2006 to 2010.¹⁸ Participants completed comprehensive questionnaires capturing information on sociodemographic characteristics, lifestyle factors and medical history at baseline. A detailed description of the recruitment process and population characteristics have been described elsewhere.¹⁹ Follow-up is ongoing and includes linkage to administrative databases, including the National Cancer and Death Registries. Participants provided written consent to the UK Biobank study personnel prior to initiating the study.

In 2009, the UK Biobank added a CRF assessment to the baseline protocol. For the current analysis, the sample was restricted to postmenopausal women who completed one of three CRF protocols (N=26 838) (see details on the assessment below).²⁰ Menopausal status at the time of CRF assessment was determined using an algorithmic approach. Women were categorised as being postmenopausal if they were >1 year older than the age their period stopped or if they had not had a period for >365 days at baseline. Women with a history of double oophorectomy at baseline were also classified as postmenopausal. Lastly, women were categorised as postmenopausal if no other information was available and they were >55 years at baseline.

Women were excluded if they had a personal history of any cancer (n=3524) or a history of mastectomy (n=18) at baseline (figure 1). As decided a priori, women with missing information on important covariates (N=5460) (eg, BMI and physical activity) were also excluded. The final sample analysed included 17 840 postmenopausal women.

Patient and public involvement

This study uses secondary data, therefore, there was no direct contact between the researchers and the participants for this study. In addition, there was no public involvement in the conceptualisation, creation or dissemination of this manuscript.

Exposure

CRF was assessed using a submaximal bicycle test without gas analysis.²⁰ Participants completed a questionnaire prior to CRF assessment to determine the risk of complications. Those classified as having minimal risk were tested at 50% of their predicted maximal workload (protocol 1), those with small risk were tested at 35% of their predicted maximal workload (protocol 2), and those with medium risk were tested at a constant workload (protocol 3). Those at high risk of an adverse event were not eligible for the general CRF protocol and therefore are not included in the study sample. Heart rate was monitored throughout, and workload was captured at the end of the CRF assessment. Linear regression, using the formula recommended in the literature, was used to interpolate workload at a predicted maximum heart rate.^{21 22} Peak oxygen consumption (VO_2 peak) was calculated using the formula: $7 + (10.8 \times \text{predicted maximum workload}) / \text{weight in kilograms}$,²³ which is the method employed for other CRF studies from the UK Biobank.^{21 22}

Estimated CRF (eCRF) was classified as a nominal three-level categorical variable: low (<20th percentile), moderate (20th to <80th percentile) and high eCRF (\geq 80th percentile) within 10-year age bands, consistent with existing CRF literature.²⁴ Alternative classifications of eCRF were also examined within 10-year age bands: (1) low fitness (less than vs greater than or equal to 20th percentile)²⁵ and (2) high fitness (less than




Figure 1 Flow chart of exclusion criteria of postmenopausal women from the UK Biobank with a valid CRF assessment. BMI, body mass index; CRF, cardiorespiratory fitness.

vs greater than or equal to 80th percentile).²⁶ Other functional forms of eCRF considered can be found in online supplemental materials.

Outcome

Time from baseline to incident cancer diagnosis was captured through linkage to the National Cancer Registry and categorised based on International Classification of Disease 10th revision (ICD-10) codes. Information on primary cause of death was obtained from the National Health Service Information Centre for participants in England and Wales, and the National Health Service Central Register for participants in Scotland. The primary outcome was a diagnosis of invasive breast cancer (ICD-10 codes C50). The occurrence of a non-breast cancer diagnosis and all-cause mortality were both treated as competing risks. Individuals were followed from baseline until the first occurrence of any of the above-mentioned outcomes or the end of the follow-up period (25 June 2021) at which point they were right censored.

Covariates

Several variables associated with CRF and/or breast cancer risk were identified as potential confounders based on existing literature. All covariates were measured at baseline/time of CRF assessment. The following covariates were treated as nominal variables: (1) race (white, black or other (Asian, mixed, other, missing)); (2) education (secondary (advanced levels, advanced subsidiary levels or equivalent; ordinary levels, general certificate of secondary education or equivalent; certificate of secondary education or equivalent), postsecondary (college or university; national vocational qualification, higher national diploma, higher national certificate or equivalent; other professional qualification (eg, teacher, nurse)) or missing (none of the above, missing)); (3) alcohol consumption (never, special occasions only, one to three times a month, once to twice a week, three or four times a week); (4) smoking status (never, current, previous); protocol (protocol 1 (minimal risk), protocol 2 (small risk), and protocol 3 (medium risk)). Protocol was examined as a nominal variable as there was no hierarchical order to protocol. Other covariates included: first degree (mother, sister, father, brother) family history of breast cancer (yes, no); number of pregnancies (nulliparous, 1, 2, ≥ 3); age at menarche (< 13 years, ≥ 13 years); physical activity (\leq or $>$ 50th percentile of metabolic task equivalent minutes of physical activity per week); BMI (underweight/normal weight (< 25 kg/m²) or overweight/obesity (≥ 25 kg/m²)); and body fat percentage measured using bioelectric impedance analysis (first quintile, yes/no)). For women with missing information for age at menarche (N=696), the median age at menarche (13 years) was used. The proportion of women using hormone replacement therapy at baseline was low (n=381, 2.1%) and adjustment for this variable did not meaningfully change the result; therefore, it was not included in the multivariable model. Self-reported physical activity was assessed using a modified version of the International Physical Activity Questionnaire short-form and MET minutes per week estimates using standard procedures.²⁷

Statistical analysis

Standardised differences were used to compare the distribution of variables by eCRF category. A mean standardised difference greater than 10% was considered clinically meaningful.²⁸

Cumulative incidence functions, stratified by the three-category eCRF variable, were estimated for invasive breast cancer (the primary outcome), where other cancers and all-cause mortality were treated as competing events. Differences in the estimates of cumulative incidence were formally compared using Gray's test.²⁹

Fine and Gray regression models³⁰ were used to examine the unadjusted and multivariable adjusted association between eCRF and hazard of breast cancer, with other cancer and all-cause mortality as competing events. Age was used as the time-scale to anchor the analysis to a clinically meaningful time point (ie, attained age, rather than time since the arbitrary baseline assessment).

Four models were produced: (1) an unadjusted model, (2) a minimally adjusted model adjusted for potential confounders of the relationship between eCRF and breast cancer (ethnicity, smoke status, alcohol frequency use and physical activity), (3) a fully adjusted model with all variables included in the minimally adjusted model and including additional established breast cancer risk factors: education, family history of breast cancer, age at menarche, number of live births, as well as protocol number and (4) fully adjusted model restricted to individuals who completed the eCRF protocol 1 (N=15 147, 84.9%).

We did not adjust for BMI or per cent body fat in any models because it was highly colinear with eCRF (Pearson's $r = -0.82$ and $r = 0.80$, respectively). Instead, we presented models stratified by BMI (overweight/obesity yes/no) and per cent body fat (first quintile yes/no) categories. This allowed us to control for the potential confounding effects of BMI and per cent body fat, and to assess whether they modified the association between eCRF and risk. Lastly, the potential impact of reverse causality on the findings were assessed using the fully adjusted model by setting the index date to 6 months, 1 year and 2 years after CRF assessment.

All analyses were conducted using SAS V.9.4; a two-sided alpha of 0.05 was considered statistically significant.

RESULTS

Table 1 shows the characteristics of the study population. The median age at eCRF assessment/baseline was 60 years (IQR 56–64) (table 1). Most women in the study sample were white (92.5%) and had completed some type of postsecondary education (60.0%). Approximately 12% of women had a first-degree relative with a history of breast cancer. The median BMI was 25.9 kg/m², the median body fat percentage was 36.8%, and the mean VO₂ peak was 20.5 mL/kg/min.

Table 2 shows the characteristics of the study population stratified by eCRF categories. The greatest imbalance in covariates was observed for BMI (mean standardised difference=223%) and body fat percentage (mean standardised difference=213%). As expected, a greater proportion of individuals in the lower fitness category also had a higher BMI and body fatness above the first quintile.

Over a median follow-up of 11.0 years (range > 0.0 to 12.2 years), 529 (3.0%) women were diagnosed with invasive breast cancer, 1623 (9.1%) with other cancers and 241 (1.4%) died (table 1). Cumulative incidence function for breast cancer with other cancers and all-cause mortality as competing events in the full study population and by eCRF category are presented in figures 2 and 3, respectively. Women with high eCRF had a lower cumulative incidence of breast cancer compared with those with low to moderate eCRF (figure 3A). However, the results of the Gray's test were not statistically significant ($p = 0.09$). Further, while women in their mid-60s to early 70s with low eCRF had a higher cumulative incidence of other cancers compared with those with moderate and high eCRF, the differences were also not statistically significant ($p = 0.30$; figure 3B). For all-cause mortality, however, the result of the Gray's test was significant ($p < 0.0001$) finding that women in their mid 60s to late-70s with

Table 1 Characteristics of postmenopausal women included in the analysis from the UK Biobank

Characteristics	N=17 840
Follow-up time (years), median (min, max)	11.0 (>0.0 to 12.2)
Age (years), median (IQR)	60 (56–64)
Age categories, n (%)	
40 to <50	869 (4.9)
50 to <60	6886 (38.6)
60 to <70	10 002 (56.1)
≥70 years	81 (0.5)
BMI (kg/m ²), median (IQR)	25.9 (23.4–29.1)
BMI categories, n (%)	
Underweight/normal weight	7332 (41.1)
Overweight	6892 (38.6)
Obesity	3616 (20.3)
Body fat percentage, median (IQR)	36.8 (32.2–41.2)
Body fat percentage categories	
First quintile (≤20th percentile)	3591 (20.1)
Second quintile (>20th to 40th percentile)	3569 (20.0)
Third quintile (>40th to 60th percentile)	3497 (19.6)
Fourth quintile (>60th to 80th percentile)	3632 (20.4)
Fifth quintile (>80th percentile)	3551 (19.9)
Ethnicity, n (%)	
White	16 502 (92.5)
Black	387 (2.2)
Other*	951 (5.3)
Education, n (%)	
Less than postsecondary†	4498 (25.2)
Postsecondary‡	10 702 (60.0)
Missing§	2640 (14.8)
Family history of breast cancer (Yes)¶, n (%)	2064 (11.6)
Age at menarche (years), median (IQR)	13.0 (12.0–14.0)
Parous (yes), n (%)	14 416 (80.8)
No of live births, median (IQR)	2 (1–2)
No of live births category, n (%)	
Nulliparous	3424 (19.2)
One	2274 (12.8)
Two	8048 (45.1)
Three or more	4094 (23.0)
Age at first birth** (years), n (%)	
<20	1050 (8.7)
20 to <25	3833 (31.6)
25 to <30	4868 (40.1)
30 to <35	1915 (15.8)
≥35	462 (3.8)
Hormone replacement therapy use, n (%)	381 (2.1)
Smoking status, n (%)	
Never	7789 (43.7)
Current	1177 (6.6)
Previous	8874 (49.7)
Alcohol frequency, n (%)	
Never	1572 (8.8)
Special occasions only	2.683 (15.0)
1–3 times a month	2175 (12.2)
Once or twice a week	4306 (24.1)
3 or 4 times a week	3833 (21.5)
Daily	3271 (18.3)
MET-minutes per week††, median (IQR)	1879.5 (924.0–3666.0)

Continued

Table 1 Continued

Characteristics	N=17 840
Protocol	
1 (minimal risk)‡‡	15 147 (84.9)
2 (small risk)§§	2064 (11.6)
3 (medium risk)¶¶	629 (3.5)
Exposure	
VO ₂ peak (mL/kg/min), mean±SD	20.5±2.1
eCRF level, n (%)	
Low eCRF	3566 (20.0)
Moderate eCRF	10 704 (60.0)
High eCRF	3570 (20.0)
Outcome	
Breast cancer, n (%)	529 (3.0)
Other cancer, n (%)	1623 (9.1)
Death, n (%)	241 (1.4)
*Asian, mixed, other and missing.	
†Advanced levels, advanced subsidiary levels or equivalent; ordinary levels, general certificate of secondary education or equivalent; certificate of secondary education or equivalent.	
‡College or university; national vocational qualification, higher national diploma, higher national certificate or equivalent; other professional qualification (eg, teacher, nurse)	
§None of the above or missing.	
¶Self-reported history of their father, mother, sister and/or brother having had breast cancer.	
**N=22 396.	
††Three types of physical activity were self reported using a modified version of the IPAQ short form: walking, moderate and vigorous physical activity. Data were cleaned using standardised procedures, and then minutes of physical activity were multiplied by corresponding MET values for walking (3.3 METs), moderate (4.0 METs) and vigorous (8.0 METs) physical activity to determine total weekly METs of physical activity.	
‡‡Participants who complete protocol 1 (aka minimal risk) for the eCRF assessment work at a maximum of 50% of their predicted workload.	
§§Participants who complete protocol 2 (aka small risk) for the eCRF assessment work at a maximum of 35% of their predicted workload.	
¶¶Participants who complete protocol 3 (aka medium risk) for the eCRF assessment worked at a constant workload.	
%, per cent; BMI, body mass index; eCRF, estimate cardiorespiratory fitness; IQR, interquartile range; max, maximum; MET, metabolic task equivalent; min, minimum; n, sample size; SD, standard deviation.	

low eCRF had the highest and women with moderate eCRF the lowest, cumulative incidence of all-cause mortality (figure 3C).

Adjusted subdistribution HR (SDHR) and 95% CIs for the relationship between eCRF and breast cancer are presented in table 3. Notably, there was a little difference in the results for the different models. In the fully adjusted model, women with high eCRF had a 24% lower risk of developing breast cancer compared with women with low to moderate eCRF (SDHR 0.76, 95% CI 0.60 to 0.97).

When models were stratified by BMI or per cent body fat, there was evidence of effect measure modification for the relationship between eCRF and breast cancer risk (table 4). Specifically, among women with overweight/obesity those with high eCRF were at a 67% (SDHR 0.33, 95% CI 0.11 to 1.01) lower risk of developing breast cancer than those with low to moderate eCRF. Conversely, women without overweight/obesity and with high eCRF did not appear to be at a significantly lower risk of developing breast cancer than those without overweight/obesity with low to moderate eCRF (SDHR 0.94, 95% CI 0.70 to 1.25). The same pattern was observed when we stratified by per cent body fat categories. Specifically, among women with per cent body fatness

Table 2 Characteristics of postmenopausal women with available eCRF assessment from the UK Biobank

Characteristics	Low eCRF	Moderate eCRF	High eCRF	Standardised differences
Sample size, n (%)	4558 (20.0)	13 675 (60.0)	4560 (20.0)	--
Follow-up time (years), median (min, max)	11.0 (0.1 to 12.0)	11.0 (>0.0 to 12.2)	11.0 (>0.0 to 12.1)	3.2
Age (years), median (IQR)	61 (56–64)	60 (56–64)	60 (56–64)	2.6
Age categories, n (%)				
40 to <50	173 (4.9)	522 (4.9)	174 (4.9)	0.1
50 to <60	1377 (38.6)	4133 (38.6)	1378 (38.6)	0.0
60 to <70	2000 (56.1)	6001 (56.1)	2001 (56.1)	0.1
≥70 years	16 (0.5)	48 (0.5)	17 (0.5)	0.3
BMI (kg/m ²), median (IQR)	32.4 (29.8–35.4)	25.9 (24.1–27.9)	22.0 (20.7–23.3)	223.1
BMI categories, n (%)				
Underweight/normal weight	63 (1.8)	3955 (37.0)	3314 (92.8)	229.5
Overweight	893 (25.0)	5743 (53.7)	256 (7.2)	76.2
Obesity	2610 (73.2)	1006 (9.4)	0 (0.0)	120.1
Body fat percentage, median (IQR)	44.1 (41.2–46.9)	36.9 (33.6–39.9)	29.5 (26.0–32.5)	212.6
Body fat percentage categories				
1st quintile (<20th percentile)	26 (0.7)	1289 (12.0)	2276 (63.8)	118.7
2nd quintile (>20th to 40th percentile)	63 (1.8)	2562 (23.9)	944 (26.4)	50.6
3rd quintile (>40th to 60th percentile)	240 (6.7)	2973 (27.8)	284 (8.0)	38.8
4th quintile (>60th to 80th percentile)	859 (24.1)	2709 (25.3)	64 (2.0)	48.8
5th quintile (>80th percentile)	2378 (66.7)	1171 (10.9)	2 (0.1)	129.4
Ethnicity				
White	3304 (92.7)	9955 (93.0)	3243 (90.8)	5.3
Black	151 (4.2)	203 (1.9)	33 (0.9)	14.3
Other*	111 (3.1)	546 (5.1)	294 (8.2)	15.0
Education, n (%)				
Less than postsecondary†	898 (25.2)	2727 (25.5)	873 (24.5)	1.6
Postsecondary‡	2080 (58.3)	6402 (59.8)	2220 (62.2)	
Missing§	420 (11.8)	1264 (11.8)	380 (10.6)	5.8
Family history of breast cancer (yes)¶, n (%)	527 (11.6)	1599 (11.7)	493 (10.8)	2.5
Age at menarche (years), median (IQR)	13.0 (11.0–14.0)	13.0 (12.0–14.0)	13.0 (12.0–14.0)	14.7
Parous (yes), n (%)	2882 (80.8)	8784 (82.1)	2750 (77.0)	8.3
No of live births, median (IQR)	2 (1–2)	2 (1–2)	2 (1–2)	9.0
No of live births category, n (%)				
Nulliparous	684 (19.2)	1920 (17.9)	820 (23.0)	8.3
One	474 (13.3)	1334 (12.5)	466 (13.1)	1.7
Two	1529 (42.9)	4975 (46.5)	1544 (43.3)	4.8
Three or more	879 (24.7)	2475 (23.1)	740 (20.7)	9.3
Age at first birth**, n (%)				
<20	265 (11.0)	620 (8.3)	165 (7.2)	7.9
20 to <25	870 (36.2)	2361 (31.7)	602 (26.4)	12.5
25 to <30	920 (38.3)	2980 (40.0)	968 (42.5)	3.1
30 to <35	283 (11.8)	1198 (16.1)	434 (19.0)	9.4
≥35	66 (2.8)	286 (3.8)	110 (4.8)	5.3
Hormone replacement therapy use, n (%)	71 (2.0)	237 (2.2)	73 (2.0)	1.0
Smoking status, n (%)				
Never	1540 (43.2)	4637 (43.3)	1612 (45.2)	2.6
Current	243 (6.8)	671 (6.3)	263 (7.4)	2.9
Previous	1783 (50.0)	5396 (50.4)	1695 (47.5)	3.9
Alcohol frequency, n (%)				
Never	386 (10.8)	833 (7.8)	353 (9.9)	7.0
Special occasions only	739 (20.7)	1472 (13.8)	472 (13.2)	13.4
1–3 times a month	542 (15.2)	1274 (11.9)	359 (10.1)	10.4
Once or twice a week	839 (23.5)	2658 (24.8)	809 (22.7)	3.4
3 or 4 times a week	623 (17.5)	2386 (22.3)	824 (23.1)	9.3
Daily	437 (12.3)	2081 (19.4)	753 (21.1)	15.9
MET-minutes per week††, median (IQR)	1473 (693.0–3013)	1908.0 (959.0–3657.0)	2228.5 (1092.0–4266.0)	20.7

Continued

Table 2 Continued

Characteristics	Low eCRF	Moderate eCRF	High eCRF	Standardised differences
Protocol				
1 (minimal risk)‡‡	2797 (78.4)	9162 (85.6)	3188 (89.3)	19.9
2 (small risk)§§	560 (15.7)	1195 (11.2)	309 (8.7)	14.5
3 (medium risk)¶¶¶	209 (5.9)	347 (3.2)	73 (2.0)	13.2
Exposure				
VO ₂ peak (mL/kg/min), mean±SD	16.9±1.1	20.5±1.2	24.3±1.5	378.8
Outcome				
Breast cancer, n (%)	115 (3.2)	329 (3.1)	85 (2.4)	3.4
Other cancer, n (%)	349 (9.9)	967 (9.0)	307 (8.6)	2.7
Death, n (%)	69 (1.9)	109 (1.0)	63 (1.8)	5.1
Crude incident rates for breast cancer (per 10 000 person-years)	31.0	29.4	22.7	--

Standardised differences greater than 10% are bolded to indicate clinically meaningful differences. One standardised difference was calculated by first calculating a unique standardised difference for all possible pairwise. Standardised differences less than 0 were multiplied by -1, and then the average of the three standardised differences was calculated.

*Asian, mixed, other and missing.

†Advanced levels, advanced subsidiary levels or equivalent; ordinary levels, general certificate of secondary education or equivalent; certificate of secondary education or equivalent.

‡College or university; national vocational qualification, higher national diploma, higher national certificate or equivalent; other professional qualification (eg, teacher, nurse).

§None of the above or missing.

¶Self-reported history of their father, mother, sister and/or brother having had breast cancer.

**Low fit n=4418, moderate fit n=13 766, high fit n=4212.

††Three types of physical activity were self reported using the modified version of the IPAQ short form: walking, moderate and vigorous physical activity. Data were cleaned using standardised procedures, and then minutes of physical activity were multiplied by corresponding MET values for walking (3.3 METs), moderate (4.0 METs) and vigorous (8.0 METs) physical activity to determine total weekly METs of physical activity.

‡‡Participants who complete protocol 1 (aka minimal risk) for the eCRF assessment work at a maximum of 50% of their predicted workload.

§§Participants who complete protocol 2 (aka small risk) for the eCRF assessment work at a maximum of 35% of their predicted workload

¶¶¶Participants who complete protocol 3 (aka medium risk) for the eCRF assessment worked at a constant workload

%, per cent; BMI, body mass index; eCRF, estimate cardiorespiratory fitness; IQR, interquartile range; max, maximum; min, minimum; n, sample size; SD, standard deviation.

above the 1st quintile, having high eCRF was associated with a 35% lower risk of developing breast cancer than women with low to moderate eCRF (SDHR 0.65, 95% CI 0.45 to 0.94). Among women with a body fat percentage within the first quintile, there was no significant association between having high eCRF and breast cancer compared with women with low to moderate eCRF (SDHR 1.41, 95% CI 0.86 to 2.32). Results from the unadjusted, minimally adjusted and fully adjusted models restricted to protocol 1 were one again similar.

Several other functional forms of eCRF were considered and results are presented in online supplemental table 1. Results were consistent when using alternative categorisations of eCRF.

To examine the potential impact of reverse causality on our results, analyses were performed setting the index date (ie, start of follow-up) to 6 months, 1 year and 2 years after CRF assessment (online supplemental table 2). In these analyses, the effect estimates for high eCRF were slightly attenuated, with wider CIs (likely due to the smaller number of events). Overall, all effect




Figure 2 Cumulative incidence function curves for invasive breast cancer, other cancers and all-cause mortality in postmenopausal women.




Figure 3 Cumulative incidence function curves for invasive breast cancer (A), other cancers (B) and all-cause mortality (C) by eCRF.

Table 3 SDHR and 95% CI for the relationship between eCRF and breast cancer among postmenopausal women in the UK Biobank

Exposure†	Unadjusted‡ (N=17 840)	Minimally adjusted‡ (N=17 840)	Fully adjusted§ (N=17 840)	Adjusted & restricted to protocol 1§ (N=15 147)
Three category fitness 1				
Low (<20th percentile) (N=3566)	Ref	Ref	Ref	Ref
Moderate (20th to <80th percentile) (N=10 704)	0.95 (0.77 to 1.18)	0.94 (0.76 to 1.17)	0.94 (0.76 to 1.16)	1.03 (0.81 to 1.32)
High (≥80th percentile) (N=3570)	0.75 (0.57 to 0.99)*	0.74 (0.56 to 0.98)*	0.73 (0.55 to 0.97)*	0.79 (0.57 to 1.08)
Low Fitness				
No (N=14 274)	Ref	Ref	Ref	Ref
Yes (N=3566)	1.11 (0.90 to 1.36)	1.12 (0.91 to 1.38)	1.13 (0.91 to 1.39)	1.03 (0.81 to 1.31)
High fitness				
No (N=14 720)	Ref	Ref	Ref	Ref
Yes (N=3570)	0.78 (0.62 to 0.98)*	0.77 (0.61 to 0.98)*	0.76 (0.60 to 0.97)*	0.77 (0.60 to 0.99)*

Fine and Gray regression analysis with other cancer, and all-cause mortality treated as competing risks was used to produce SDHRs. Age was used as a timescale to anchor findings to a clinically meaningful time point instead of arbitrary time point (ie, time since CRF assessment).

*Statistically significant ($p < 0.05$).

†Sample sizes are based on the whole sample (ie, all those with an eCRF assessment using any of the three protocols).

‡Estimates adjusted for ethnicity (white, black, other), smoke status (never, current, previous), alcohol use frequency (never, special occasions only, 1–3 times a month, once or twice a week, 3 or 4 times a week, daily) and physical activity (categorised as ≤50th percentile vs >50th percentile of MET minutes per week).

§Estimates are adjusted for all variables in the minimally adjusted model and education (secondary, postsecondary, missing), family history of breast cancer, age at menarche (<or≥13 years of age), number of live births (nulliparous, 1, 2, 3 or more children) and protocol (1, 2, 3) if relevant.

BMI, body mass index; CI, confidence interval; eCRF, estimated cardiorespiratory fitness; SDHR, subdistribution HR.

estimates remained below one and were similar regardless of the number of events excluded, and the model presented.

DISCUSSION

In this population of postmenopausal, primarily white, women from the UK Biobank, we observed that having high eCRF was associated with an approximately 24% lower risk of breast cancer compared with having low or moderate eCRF. However, when we stratified by BMI or per cent body fat, the estimated association for eCRF was limited to individuals with overweight/obesity or per cent body fat above the first quintile and not in their leaner counterparts. Taken together, this may suggest that CRF is a protective factor for breast cancer, but only among women with overweight/obesity or those with per cent body fat above the first quintile.

Previous research has found that having a higher CRF can decrease a person's risk of developing³¹ and dying from cardiometabolic conditions,³² but the relationship between CRF and breast cancer incidence has not been examined. One study to date has examined the association between CRF and breast cancer mortality in women, finding that higher CRF is associated with lower breast cancer mortality.³³ Consistent with these findings, we observed that women with high eCRF have a lower risk of breast cancer.

CRF increases as a result of sustained physical activity. It is well established that increased physical activity can decrease a woman's risk of developing breast cancer.^{34 35} In fact, a meta-analysis of 73 studies that incorporated many different physical activity assessments observed that women who participate in physical activity have, on average, a 25% lower risk of breast cancer.³⁴ This association was more pronounced in women who participated in sustained moderate to vigorous physical activity, or physical activity across their lifetime.³⁴ This could suggest that physical activity alone is not enough to reduce a woman's risk of breast cancer but rather the improvement in CRF is what is decreasing risk. Consistent with this, in the current study, eCRF was associated with a significantly lower risk of breast cancer even after adjustment for physical activity. In fact, the effect estimate for eCRF was essentially unchanged. These findings suggest that participation in sustained physical activity leading

to increased CRF may be necessary to significantly lower a woman's risk of developing breast cancer.

Several functional forms of eCRF were assessed. Despite this, only estimates of high eCRF such as those in the 60th–75th percentile or greater were significantly associated with risk. Prior studies have observed a dose response relationship between CRF and non-cancer-related outcomes and death.^{36–38} In the current study, we did not observe a dose response. Instead, we observed a potential threshold effect of high eCRF. This may mean that a higher level of CRF is needed to have meaningful improvements in breast cancer risk. However, CRF values from the Cooper Clinic in the USA, which first proposed percentile cut-offs for characterising the association between CRF and health risk are substantially higher than those that would likely be seen in the general population. The Fitness Registry and the Importance of Exercise National Database (FRIEND) cohort was developed to determine normative CRF values in the USA. They found that while the 25th percentile of VO_2 max for women between the ages of 60–69 (which is similar to the median age in the current study) at the Cooper Clinic was 25.1 mL/kg/min,³⁹ women of the same age in the FRIEND cohort who were in the 75th percentile had a VO_2 max of 23.8 mL/kg/min. The VO_2 max reported in the FRIEND cohort is similar to the 75th percentile of VO_2 peak for the current study (22.2 mL/kg/min). This suggests that the 20th percentile CRF cut-off (proposed by the Cooper Clinic) and observed as having a protective association with health outcomes is more closely associated with our 80th percentile cut-off and may contribute to why we observed our threshold effect. The issue of unrepresentative CRF thresholds is not restricted to the Cooper Clinic study. Several cohorts^{40 41} with CRF measurements (eg, the National Health and Nutrition Examination Survey) also have substantially higher CRF values than what would be expected in the general population (ie, individuals in the FRIEND cohort). The higher CRF values present in these existing cohorts suggest a need for more representative CRF cohort studies to establish relevant thresholds related to CRF, and risk of disease and death.

A bidirectional relationship is thought to exist between CRF and both BMI and per cent body fat. That is, having a higher CRF is associated with a lower body fat percentage.⁴² Conversely, having

Table 4 SDHR (95% CI) for the relationship between eCRF and breast cancer risk stratified by category of BMI and per cent body fat among postmenopausal women from the UK Biobank

Exposure	Unadjusted† (N=17 840)		Minimally adjusted†† (N=17 840)		Fully adjusted†‡§ (N=17 840)		Adjusted and restricted to protocol 1†§ (N=15 147)	
	Without OWOB (N=7332)	With OWOB (N=10 508)	Without OWOB (N=7332)	With OWOB (N=10 508)	Without OWOB (N=7332)	With OWOB (N=10 508)	Without OWOB (N=6518)	With OWOB (N=8629)
BMI categories								
High fitness								
No¶	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
Yes**	0.91 (0.69 to 1.21)	0.33 (0.11 to 1.02)	0.94 (0.71 to 1.25)	0.33 (0.10 to 1.01)	0.94 (0.70 to 1.25)	0.33 (0.11 to 1.01)	0.89 (0.66 to 1.21)	0.38 (0.12 to 1.18)
Quintiles of per cent body fat								
1st quintile (N=3737)	1st quintile (N=3737)	2nd–5th quintile (N=14 103)	1st quintile (N=3737)	2nd–5th quintile (N=14 103)	1st quintile (N=3737)	2nd–5th quintile (N=14 103)	Low body fat (N=3360)	High body fat (N=11 787)
High fitness								
No††	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
Yes††	1.38 (0.85 to 2.25)	0.66 (0.45 to 0.96)*	1.40 (0.86 to 2.29)	0.66 (0.45 to 0.95)*	1.41 (0.86 to 2.32)	0.65 (0.45 to 0.94)*	1.33 (0.79 to 2.24)	0.68 (0.46 to 1.00)

Fine and Gray regression analysis with other cancer, and all-cause mortality treated as competing risks was used to produce SDHRs. Age was used as a timescale to anchor findings to a clinically meaningful time point instead of arbitrary time point (ie, time since CRF assessment).

*Statistically significant ($p < 0.05$).

†Sample sizes are based on the whole sample (ie, all those with an eCRF assessment using any of the three protocols).

††Estimates adjusted for ethnicity (white, black, other), smoke status (never, current, previous), alcohol use frequency (never, special occasions only, 1–3 times a month, once or twice a week, 3 or 4 times a week, daily) and physical activity (categorised as ≤ 50 th percentile versus > 50 th percentile of MET minutes per week).

‡Estimates are adjusted for all variables in the minimally adjusted model and education (secondary, postsecondary, missing), family history of breast cancer, age at menarche ($> \text{or} \geq 13$ years of age), number of live births (nulliparous, 1, 2, 3 or more children) and protocol (1, 2, 3) if relevant.

§Sample size in whole population is $n=4018$ and $n=10 252$ for without and with overweight/obesity, respectively.

**Sample size in whole population is $n=3314$ and $n=256$ for without and with overweight/obesity, respectively.

††Sample size in whole population is $n=1315$ and $n=12 955$ for body fat within and greater than the first quintile, respectively.

‡‡Sample size in whole population is $n=2276$ and $n=1294$ for body fat within and greater than the first quintile, respectively.

BMI, body mass index; eCRF, estimated cardiorespiratory fitness; MET, metabolic task equivalent; OWOB, overweight/obesity; SDHR, subdistribution HR.

higher levels of body fat is associated with a lower CRF.⁴³ CRF and BMI have also each been found to modify the association of the other with chronic diseases such as diabetes^{44,45} and all-cause mortality.⁴⁶ When we stratified by BMI or per cent body fat, individuals with overweight/obesity or per cent body fat above the first quintile with high eCRF were at a lower risk of breast cancer than those with low to moderate eCRF, but not their leaner counterparts with similar CRF levels. While BMI and per cent body fat may still be cofounders of the relationship between eCRF and breast cancer, the fact that the effect estimates were different depending on the category of BMI and per cent body fat is also suggestive of effect measure modification. This could be mechanistically explained by the relationship between body fatness, physical activity and eCRF to oestrogen and chronic inflammation.

Following menopause, body fat becomes the primary source of oestrogen in the body⁴⁷ and oestrogen exposure is strongly associated with breast cancer risk.⁴⁸ Obesity is associated with chronic systemic inflammation.^{49–52} In addition to oestrogen, chronic inflammation is thought to mediate the relationship between obesity and an increased risk of breast cancer in postmenopausal women.⁵³ Conversely, higher CRF and physical activity are associated with both lower levels of circulating endogenous estrogen^{54,55} and lower levels of systemic inflammation.^{51,52,56} Given CRF and measures of body fatness may both impact breast cancer risk through similar pathways may explain why CRF is only associated with a lower risk among those with elevated body fatness as individuals may need to have elevated inflammation or oestrogen in order to see a benefit.

Given that some events occurred shortly after CRF assessment, there is a potential for reverse causality. Although one study suggested that women with a recent breast cancer diagnosis have lower CRF than sedentary women without a history of cancer,⁵⁷ the comparison was biased as controls that were younger and leaner, both factors associated with a higher CRF. There is no paper that has repeat measures of CRF in women prior to and at diagnosis of breast cancer, but early-stage breast cancer is primary an asymptomatic disorder. It is therefore unlikely that it is associated with lower CRF levels. Nonetheless, we assessed for the potential impact of reverse causality in sensitivity analyses by setting the index date to 6 months, 1 year and 2 years after CRF assessment. Using the new index date there was an attenuation of the effect estimate (from 24% to 16% lower risk) along with reduced precision, which could suggest some impact of reverse causality on the results. However, all the effect estimates remained below one, and the attenuation of the effect estimates was similar when the index was set to 6 months and 2 years post-CRF assessment, with the reduction in precision likely due to the smaller number of events. These results support the findings that CRF may be an independent predictor of breast cancer risk and identify the need for future studies to assess CRF over time to determine if CRF can change as a result of breast cancer.

There are several strengths and limitations of the current analysis that warrant mentioning. A limitation is that the gold-standard method for capturing CRF (ie, a maximal treadmill test with oxygen expiration capture) was not used. Further, participants completed slightly different versions of the CRF assessment based on their estimated risk of adverse events, potentially introducing some measurement error into the analysis. To account for this potential measurement bias, we conducted an analysis restricted to those with protocol 1 (the protocol most closely resembling a submaximal CRF assessment). Overall, results were similar to those reported in the full sample. We also only had one measurement of eCRF per participant, which does not allow us to explore the impact of temporal changes

in this measurement over time or how these temporal changes may impact risk. Nonetheless, exercise-based CRF assessments are rare, thus the availability of a submaximal assessment to estimate CRF on more than 17 500 participants is a strength of this study. Lastly, approximately 93% of participants in our sample from the UK Biobank identified as white, which may mean our findings do not generalise to non-white populations.

Other important strengths include the quality of other measures: (1) weight and height were measured by trained professionals; (2) many cofounders were captured using standardised questionnaires that used the same wording as other established population-based cohorts and (3) outcome measures were assessed by administrative databases in a publicly funded healthcare system, allowing for complete follow-up. While there are multiple methods to assess body fat, dual-X-ray-absorptiometry is often considered the gold standard. However, dual-X-ray-absorptiometry assessed body fat was only available for a small proportion of individuals who also had a CRF assessment and there were very few events in this group (n=1). However, per cent body fat assessed using bioelectrical impedance analysis was available in most individuals. Notably, research from the UK Biobank found that results for the association between body fat and breast cancer risk were similar whether per cent body fat was assessed using dual-X-ray-absorptiometry or bioelectrical impedance analysis.⁵⁸

Menopausal status is an important modifier for some breast cancer risk factors including BMI⁶ and physical activity.⁵⁹ Since most women in the sample were 50 years or older at baseline, we could not examine the association between CRF and risk in premenopausal women. This remains an important area of study for future research. We also had limited information on dietary habits. While dietary information is available through the UK Biobank, there is only limited evidence that a few dietary factors may be associated with a woman's risk of developing breast cancer⁶⁰ and some of these (eg, calcium intake) were not measured by the UK Biobank.

In conclusion, this is the first study to examine the relationship between eCRF and breast cancer risk. Findings from this study suggest that high eCRF may be a protective factor for breast cancer in postmenopausal women, in particular those with overweight/obesity or per cent body fat above the first quintile. This work contributes to our understanding of the relationship between several interrelated risk factors for breast cancer (eg, elevated body fatness, physical inactivity) with the goal of informing preventive interventions. Findings from this study support the notion that physical activity, with the particular goal of increasing CRF, may be beneficial to reduce breast cancer risk in postmenopausal with an elevated body fat.

Twitter Rebecca A G Christensen @DrBeccaPhD

Acknowledgements This work would not have been possible without all the volunteers for the UK Biobank Study, and the UK Biobank study data which was made available under the application number: 52609.

Contributors RAG was responsible for: conceptualisation, data curation, formal analysis, methodology, software and writing—original draft, and takes overall responsibility as the guarantor. JAK was responsible for the conceptualisation and writing—review and editing. RS was responsible for conceptualisation, methodology and writing—review and editing. JDB was responsible for conceptualisation, supervision and writing—review and editing.

Funding This project was funded in part by Canadian Institutes of Health Research (grant no: RN312225-376411) and discretionary funds held by JDB.

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not applicable.

Ethics approval This study involves human participants and was approved by University of Toronto (#38620). Participants gave informed consent to participate in the study before taking part.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data may be obtained from a third party and are not publicly available. Data are owned by the UK Biobank study. Qualified researchers can access the data by completing a short application form and paying a data access fee.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

ORCID iD

Rebecca A G Christensen <http://orcid.org/0000-0001-5212-8688>

REFERENCES

- Negri E, Braga C, La Vecchia C, et al. Family history of cancer and risk of breast cancer. *Int J Cancer* 1997;72:735–8.
- Momenimovahed Z, Salehiniya H. Epidemiological characteristics of and risk factors for breast cancer in the world. *Breast Cancer (Dove Med Press)* 2019;11:151–64.
- Shah NR, Borenstein J, Dubois RW. Postmenopausal hormone therapy and breast cancer: a systematic review and meta-analysis. *Menopause* 2005;12:668–78.
- Anothaisintawee T, Wiratkapun C, Lertsittichai P, et al. Risk factors of breast cancer: a systematic review and meta-analysis. *Asia Pac J Public Health* 2013;25:368–87.
- Hamajima N, Hirose K, Tajima K. Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies. *The Lancet Oncology* 2012;13:1141–51.
- Cheraghi Z, Poorolajal J, Hashem T, et al. Effect of body mass index on breast cancer during premenopausal and postmenopausal periods: a meta-analysis. *PLoS One* 2012;7:e51446.
- Wang J, Yang DL, Chen ZZ, et al. Associations of body mass index with cancer incidence among populations, genders, and menopausal status: a systematic review and meta-analysis. *Cancer Epidemiol* 2016;42:1–8.
- Chan DSM, Abar L, Cariolou M, et al. World cancer research fund International: continuous update project—systematic literature review and meta-analysis of observational cohort studies on physical activity, sedentary behavior, adiposity, and weight change and breast cancer risk. *Cancer Causes Control* 2019;30:1183–200.
- Skinner JS, Wilmore KM, Krasnoff JB, et al. Adaptation to a standardized training program and changes in fitness in a large, heterogeneous population: the HERITAGE family study. *Med Sci Sports Exerc* 2000;32:157–61.
- Suminski RR, Wier LT, Poston W, et al. The effect of habitual smoking on measured and predicted Vo2max. *J Phys Act Health* 2009;6:667–73.
- Hingorjo MR, Zehra S, Hasan Z, et al. Cardiorespiratory fitness and its association with adiposity indices in young adults. *Pak J Med Sci* 2017;33.
- Prabha V, Padmanabha BV, Doddamani BR. Correlation between obesity and cardiorespiratory fitness. *Int J Curr Biol Med Sci* 2014;5:1193–6.
- Bouchard C, Sarzynski MA, Rice TK, et al. Genomic predictors of the maximal O2 uptake response to standardized exercise training programs. *J Appl Physiol (1985)* 2011;110:1160–70.
- Koch LG, Britton SL, Wisløff U. A rat model system to study complex disease risks, fitness, aging, and longevity. *Trends Cardiovasc Med* 2012;22:29–34.
- Wisløff U, Najjar SM, Ellingsen O, et al. Cardiovascular risk factors emerge after artificial selection for low aerobic capacity. *Science* 2005;307:418–20.
- Kodama S, Saito K, Tanaka S, et al. Cardiorespiratory fitness as a quantitative predictor of all-cause mortality and cardiovascular events in healthy men and women: a meta-analysis. *JAMA* 2009;301:2024–35.
- Thompson HJ, Jones LW, Koch LG, et al. Inherent aerobic capacity-dependent differences in breast carcinogenesis. *Carcinogenesis* 2017;38:920–8.
- UK Biobank Coordinating Centre. UK Biobank: protocol for a large-scale prospective epidemiological resource. 2007. Available: <https://www.ukbiobank.ac.uk/wp-content/uploads/2011/11/UK-Biobank-Protocol.pdf> [Accessed 20 Mar 2019].
- Fry A, Littlejohns TJ, Sudlow C, et al. Comparison of sociodemographic and health-related characteristics of UK Biobank participants with those of the general population. *Am J Epidemiol* 2017;186:1026–34.
- UK Biobank. Cardio assessment version 1.0.; 2011. Available: <http://www.ukbiobank.ac.uk/> [Accessed 17 Mar 2019].
- Kim Y, White T, Wijndaele K, et al. The combination of cardiorespiratory fitness and muscle strength, and mortality risk. *Eur J Epidemiol* 2018;33:953–64.
- Celis-Morales CA, Lyall DM, Anderson J, et al. The association between physical activity and risk of mortality is modulated by grip strength and cardiorespiratory fitness: evidence from 498 135 UK-Biobank participants. *Eur Heart J* 2017;38:116–22.
- Swain DP. Energy cost calculations for exercise prescription: an update. *Sports Med* 2000;30:17–22.
- Farrell SW, Finley CE, McAuley PA, et al. Cardiorespiratory fitness, different measures of adiposity, and total cancer mortality in women. *Obesity (Silver Spring)* 2011;19:2261–7.
- Wei M, Kampert JB, Barlow CE. Relationship between low cardiorespiratory fitness and mortality in normal-weight, overweight, and obese men. *JAMA* 1999;282:1547.
- Hoehner CM, Barlow CE, Allen P, et al. Commuting distance, cardiorespiratory fitness, and metabolic risk. *Am J Prev Med* 2012;42:571–8.
- Guidelines for data processing and analysis of the International physical activity questionnaire (IPAQ) - short and long form. 2005. Available: https://www.researchgate.net/publication/267932370_Guidelines_for_data_processing_and_analysis_of_the_International_Physical_Activity_Questionnaire_IPAQ2005_URL_httpwwwIPAQkise
- Austin PC. Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. *Communications in Statistics - Simulation and Computation* 2009;38:1228–34.
- Dignam JJ, Kocherginsky MN. Choice and interpretation of statistical tests used when competing risks are present. *J Clin Oncol* 2008;26:4027–34.
- Latouche A, Allignol A, Beyersmann J, et al. A competing risks analysis should report results on all cause-specific hazards and cumulative incidence functions. *J Clin Epidemiol* 2013;66:648–53.
- Kodama S, Saito K, Tanaka S. Cardiorespiratory fitness as a quantitative predictor of all-cause mortality and cardiovascular events in healthy men and women: a meta-analysis. *JAMA* 2009;301:2024.
- Katzmarzyk PT, Church TS, Blair SN. Cardiorespiratory fitness attenuates the effects of the metabolic syndrome on all-cause and cardiovascular disease mortality in men. *Arch Intern Med* 2004;164:1092–7.
- Peel JB, Sui X, Adams SA, et al. A prospective study of cardiorespiratory fitness and breast cancer mortality. *Med Sci Sports Exerc* 2009;41:742–8.
- Lynch BM, Neilson HK, Friedenreich CM. Physical activity and breast cancer prevention. *Recent Results Cancer Res* 2011;186:13–42.
- Lahart IM, Metsios GS, Nevill AM, et al. Physical activity, risk of death and recurrence in breast cancer survivors: a systematic review and meta-analysis of epidemiological studies. *Acta Oncologica* 2015;54:635–54.
- Sui X, LaMonte MJ, Blair SN. Cardiorespiratory fitness and risk of nonfatal cardiovascular disease in women and men with hypertension. *Am J Hypertens* 2007;20:608–15.
- Carnethon MR, Gulati M, Greenland P. Prevalence and cardiovascular disease correlates of low cardiorespiratory fitness in adolescents and adults. *JAMA* 2005;294:2981–8.
- Farrell SW, Barlow CE, Willis BL, et al. Cardiorespiratory fitness, different measures of adiposity, and cardiovascular disease mortality risk in women. *J Womens Health (Larchmt)* 2020;29:319–26.
- Kaminsky LA, Imboden MT, Arena R, et al. Reference standards for cardiorespiratory fitness measured with cardiopulmonary exercise testing using cycle ergometry: data from the fitness registry and the importance of exercise national database (FRIEND) registry. *Mayo Clinic Proceedings* 2017;92:228–33.
- Cao C, Yang L, Cade WT, et al. Cardiorespiratory fitness is associated with early death among healthy young and middle-aged baby boomers and generation Xers. *Am J Med* 2020;133:961–8.
- Eklblom-Bak E, Eklblom B, Söderling J, et al. Sex- and age-specific associations between cardiorespiratory fitness, CVD morbidity and all-cause mortality in 266 109 adults. *Prev Med* 2019;127:105799.
- Wong SL, Katzmarzyk PT, Nichaman MZ, et al. Cardiorespiratory fitness is associated with lower abdominal fat independent of body mass index. *Med Sci Sports Exerc* 2004;36:286–91.
- Beaudry RI, Kirkham AA, Thompson RB, et al. Exercise intolerance in anthracycline-treated breast cancer survivors: the role of skeletal muscle bioenergetics, oxygenation, and composition. *Oncologist* 2020;25:e852–60.
- Wei M, Gibbons LW, Mitchell TL, et al. The association between cardiorespiratory fitness and impaired fasting glucose and type 2 diabetes mellitus in men. *Ann Intern Med* 1999;130:89–96.
- Lee DC, Sui X, Church TS, et al. Associations of cardiorespiratory fitness and obesity with risks of impaired fasting glucose and type 2 diabetes in men. *Diabetes Care* 2009;32:257–62.
- Blair SN, Kohl HW, Paffenbarger RS, et al. Physical fitness and all-cause mortality: a prospective study of healthy men and women. *JAMA* 1989;262:2395–401.
- Cleary MP, Grossmann ME. Obesity and breast cancer: the estrogen connection. *Endocrinology* 2009;150:2537–42.
- Clemons M, Goss P. Estrogen and the risk of breast cancer. *N Engl J Med* 2001;344:276–85.
- Ash C, Smith J, Alderton G. Obesity and inflammation. *Science* 2020;370:419.
- Kuroda M, Sakaue H. Adipocyte death and chronic inflammation in obesity. *J Med Invest* 2017;64:193–6.

- 51 Lavie CJ, Church TS, Milani RV, *et al.* Impact of physical activity, cardiorespiratory fitness, and exercise training on markers of inflammation. *J Cardiopulm Rehabil Prev* 2011;31:137–45.
- 52 Madssen E, Skaug E-A, Wisløff U, *et al.* Inflammation is strongly associated with cardiorespiratory fitness, sex, BMI, and the metabolic syndrome in a self-reported healthy population: HUNT3 fitness study. *Mayo Clin Proc* 2019;94:803–10.
- 53 Crespi E, Bottai G, Santaripa L. Role of inflammation in obesity-related breast cancer. *Curr Opin Pharmacol* 2016;31:114–22.
- 54 Matthews CE, Sampson JN, Brenner DR, *et al.* Effects of exercise and cardiorespiratory fitness on estrogen metabolism in postmenopausal women. *Cancer Epidemiol Biomarkers Prev* 2018;27:1480–2.
- 55 McTiernan A, Tworoger SS, Ulrich CM, *et al.* Effect of exercise on serum estrogens in postmenopausal women: a 12-month randomized clinical trial. *Cancer Res* 2004;64:2923–8.
- 56 Beavers KM, Brinkley TE, Nicklas BJ. Effect of exercise training on chronic inflammation. *Clin Chim Acta* 2010;411:785–93.
- 57 Peel AB, Thomas SM, Dittus K, *et al.* Cardiorespiratory fitness in breast cancer patients: a call for normative values. *J Am Heart Assoc* 2014;3:e000432.
- 58 Guo W, Key TJ, Reeves GK. Adiposity and breast cancer risk in postmenopausal women: results from the UK Biobank prospective cohort. *Int J Cancer* 2018;143:1037–46.
- 59 Friedenreich CM, Cust AE. Physical activity and breast cancer risk: impact of timing, type and dose of activity and population subgroup effects. *Br J Sports Med* 2008;42:636–47.
- 60 World Cancer Research Fund, American Institute for Cancer Research. Diet, nutrition, physical activity and breast cancer. Continuous update project expert report 2018. 2018. Available: <https://www.wcrf.org/wp-content/uploads/2021/02/Breast-cancer-report.pdf> [Accessed 14 May 2022].

Supplementary Table 1: SDHR and 95%CI for different functional forms of eCRF and their association with invasive breast cancer

Exposure	Unadjusted (N=17,840)	Minimally adjusted ¹ (N=17,840)	Fully adjusted ² (N=17,840)	Fully adjusted and restricted to 1 st protocol ² (N=15,147)
Tertiles				
0 to 33.3	Ref	Ref	Ref	Ref
≥33.3 to <66.6	1.13 (0.93, 1.39)	1.13 (0.92, 1.38)	1.11 (0.91, 1.36)	1.19 (0.95, 1.49)
≥66.6	0.85 (0.69, 1.06)	0.85 (0.68, 1.06)	0.84 (0.67, 1.04)	0.90 (0.71, 1.15)
≥66.6 th percentile Yes versus No	0.80 (0.66, 0.97)	0.80 (0.66, 0.96)	0.79 (0.65, 0.96)	0.82 (0.67, 1.01)
Quartiles				
0 to 25	Ref	Ref	Ref	Ref
≥25 to 50	0.99 (0.79, 1.26)	0.98 (0.78, 1.24)	0.98 (0.78, 1.24)	1.04 (0.80, 1.35)
≥50 to 75	1.00 (0.80, 1.27)	1.00 (0.79, 1.26)	0.99 (0.78, 1.25)	1.08 (0.83, 1.41)
≥75	0.75 (0.58, 0.96)	0.73 (0.57, 0.95)	0.72 (0.56, 0.93)	0.76 (0.57, 1.01)
≥75 th percentile Yes versus No	0.74 (0.60, 0.92)	0.74 (0.59, 0.92)	0.73 (0.59, 0.91)	0.73 (0.58, 0.92)
Three-category variable				
Low (<20 th percentile)	Ref	Ref	Ref	Ref
Moderate (20 th -<60 th percentile)	1.00 (0.80, 1.26)	0.99 (0.79, 1.24)	0.99 (0.79, 1.24)	1.07 (0.83, 1.38)
High (≥60 th percentile)	0.80 (0.63, 1.01)	0.79 (0.62, 1.00)	0.78 (0.61, 0.99)	0.87 (0.66, 1.14)
≥60 th percentile Yes versus No	0.80 (0.67, 0.96)	0.79 (0.66, 0.95)	0.79 (0.66, 0.94)	0.83 (0.68, 1.01)
VO ₂ peak (ml/kg/min) per 5 unit	0.86 (0.74, 1.02)	0.84 (0.72, 1.00)	0.85 (0.72, 1.00)	0.88 (0.74, 1.06)
16.8 ml/kg/min category	0.88 (0.65, 1.18)	0.86 (0.64, 1.17)	0.86 (0.64, 1.17)	0.87 (0.61, 1.24)
METs per 1-unit increase	0.90 (0.81, 1.01)	0.89 (0.79, 1.00)	0.89 (0.79, 1.00)	0.92 (0.81, 1.04)
METs per 5-unit increase	0.60 (0.34, 1.06)	0.58 (0.32, 1.04)	0.55 (0.31, 0.99)	0.65 (0.34, 1.21)
METs category				
≥ 5 METs (Yes)	0.88 (0.69, 1.12)	0.86 (0.68, 1.11)	0.86 (0.67, 1.10)	0.90 (0.68, 1.20)
Natural Cubic Splines for 1 unit increase in VO ₂ peak				
Knot 1	Ref	Ref	Ref	Ref
Knot 2	0.99 (0.93, 1.05)	0.98 (0.93, 1.04)	0.98 (0.93, 1.04)	1.01 (0.94, 1.08)
Knot 3	1.00 (0.99, 1.01)	1.00 (0.99, 1.01)	1.00 (0.99, 1.01)	0.99 (0.98, 1.01)

Natural Cubic Splines for 5 unit increase in VO ₂ peak				
Knot 1	Ref	Ref	Ref	Ref
Knot 2	0.94 (0.70, 1.25)	0.92 (0.68, 1.23)	0.91 (0.68, 1.22)	1.03 (0.73, 1.44)
Knot 3	0.92 (0.71, 1.18)	0.93 (0.72, 1.20)	0.92 (0.71, 1.19)	0.86 (0.65, 1.14)
Natural Cubic Splines for 1 unit increase in METs				
Knot 1	Ref	Ref	Ref	Ref
Knot 2	0.95 (0.78, 1.17)	0.94 (0.77, 1.16)	0.94 (0.76, 1.15)	1.02 (0.80, 1.29)
Knot 3	0.96 (0.85, 1.09)	0.96 (0.85, 1.09)	0.96 (0.85, 1.09)	0.93 (0.81, 1.07)
Natural Cubic Splines for 5 unit increase in METs				
Knot 1	Ref	Ref	Ref	Ref
Knot 2	0.79 (0.29, 2.20)	0.74 (0.26, 2.08)	0.73 (0.26, 2.03)	1.10 (0.34, 3.57)
Knot 3	0.35 (0.02, 7.83)	0.40 (0.02, 9.05)	0.37 (0.02, 8.57)	0.16 (0.00, 5.12)

Abbreviations: METs, metabolic equivalent tasks

Bolded values have a p-value less than 0.05.

Fine and Gray regression analysis with other cancer, and all-cause mortality treated as competing risks was used to produce SDHRs.

Age was used as a timescale to anchor findings to a clinically meaningful timepoint instead of arbitrary time point (i.e., time since CRF assessment).

¹Estimates adjusted for ethnicity (white, Black, other), smoke status (never, current, previous), alcohol use frequency (never, special occasions only, one to three times a month, once or twice a week, three or four times a week, daily), and physical activity (categorized as $\leq 50^{\text{th}}$ percentile versus $> 50^{\text{th}}$ percentile of MET minutes per week)

²Estimates are adjusted for all variables in the minimally adjusted model and education (secondary, post-secondary, missing), family history of breast cancer, age at menarche ($<$ or ≥ 13 years of age), number of live births (nulliparous, one, two, three or more children), and protocol (1, 2, 3) if relevant.

Supplementary Table 2: SDHR (95% CI) for the relationship between eCRF and breast cancer risk setting index to 6 months, 1 year and 2 years after CRF assessment

Exposure	Unadjusted	Minimally adjusted ¹	Fully adjusted ²	Adjusted & restricted to protocol 1 ²
	Excluding events within the first 6 months			
High eCRF (Yes versus No)	0.83 (0.65, 1.05)	0.82 (0.65, 1.04)	0.82 (0.64, 1.04)	0.83 (0.64, 1.07)
	Excluding event within the first year			
High eCRF (Yes versus No)	0.86 (0.68, 1.09)	0.85 (0.68, 1.08)	0.84 (0.66, 1.07)	0.85 (0.66, 1.10)
	Excluding events within the first 2 years			
High eCRF (Yes versus No)	0.82 (0.64, 1.05)	0.81 (0.63, 1.05)	0.84 (0.62, 1.04)	0.81 (0.62, 1.07)

*Statistically Significant (P<0.05)

Fine and Gray regression analysis with other cancer, and all-cause mortality treated as competing risks was used to produce SDHRs. Age was used as a timescale to anchor findings to a clinically meaningful timepoint instead of arbitrary time point (i.e., time since CRF assessment).

¹Estimates adjusted for ethnicity (white, Black, other), smoke status (never, current, previous), alcohol use frequency (never, special occasions only, one to three times a month, once or twice a week, three or four times a week, daily), and physical activity (categorized as ≤50th percentile versus >50th percentile of MET minutes per week)

²Estimates are adjusted for all variables in the minimally adjusted model and education (secondary, post-secondary, missing), family history of breast cancer, age at menarche (< or ≥13 years of age), number of live births (nulliparous, one, two, three or more children), and protocol (1, 2, 3) if relevant.